News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Health Robotics and Grifols Expand Marketing Cooperation Into the United States of America, Replacing McKesson


7/25/2011 11:37:42 AM

BOZEN, SUD-TIROL, Italy, July 25, 2011 /PRNewswire/ --


Health Robotics today announced an additional key step in its previously broadcasted program to replace McKesson Automation http://www.health-robotics.com/smartedit/downloads/en/mck.pdf with the extension of its already successful European partnership with Grifols to comprise the companies' joint marketing in the United States of America. Under the expanded agreement, Grifols' operating subsidiary in Los Angeles will co-market Health Robotics' i.v.STATION, i.v.SOFT, and i.v.STATION ONCO world-leading solutions to Health-System Pharmacies in the USA.

"After visiting Health Robotics' Robot factory and participating in its technical training this month, I'm very excited to represent Health Robotics' unique IV Automation solutions in the USA, in conjunction with Grifols USA's Hospital Division portfolio of products. Bringing Grifols' collective experience from our Health Robotics' European IV Robot installations to the United States, I look forward to develop unique value propositions for our American customers, reflecting the exclusive patient safety and financial benefits of i.v.STATION, i.v.SOFT, and i.v.STATION ONCO"stated Juan Miguel Cana, Grifols USA Hospital Division's General Manager.

"Grifols' cooperation in the USA represents a very positive step in the post-McKesson era for Health Robotics' products in America, giving our company access to an experienced, sizeable, and dedicated Sterile Compounding team. Furthermore, with the release of 1H2011 results next week, 2 additional key partnerships between Health Robotics with American companies will be announced, persisting on the McKesson-replacement strategy path" stated Gaspar DeViedma, Health Robotics' Executive Vice President.

About Grifols:

Grifols is a Spanish holding company, specializing in the hospital-pharmaceutical sector, and with a presence in over 90 countries. Since May 2006 it has been listed on the Spanish Continuous Market, and since 2008 it has been included in the Ibex-35. Grifols is the leading European plasma products company, and the fourth-largest producer in the world. The company plans to strengthen its position within the industry as a vertically integrated company, on the basis of its completed investments and its ongoing program for the period 2008-2012. In terms of raw material, Grifols has secure plasma supplies from its network of 80 plasmapheresis centers in the United States, while its production plants in Barcelona (Spain) and Los Angeles (United States) ensure that it has the fractionation capacity to satisfy rising demand. In addition, the company has implemented an ambitious investment plan to enable it to deliver sustained growth over the next 8 to 10 years. Grifols' Hospital Division focuses on research, development, manufacturing and marketing non-biological products used in hospitals, clinics and infusion centers. Grifols' Hospital Division products are designed to increase safety and efficiency in the hospital pharmacy. For more information, please visit http://www.grifols.com

About Health Robotics:

Founded in 2006, Health Robotics is the undisputed global leading supplier of life-critical intravenous medication robots, winning 100% of all worldwide IV Robot's publicly announced purchases over the past 18 months, and providing more than 200 hospital installations in 6 continents with robotics-based technology and software automation solutions. Health Robotics' world-leading solutions CytoCare® and i.v.STATION® ONCO [hazardous IVs], i.v.STATION® [non-hazardous IVs], i.v.SOFT® [workflow engine for manual compounding], MEDarchiver® [life-critical clinical information system], and TPNstation [totally-automated parenteral nutrition] have and will greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' products help hospitals eliminate life-threatening drug and diluent exchange errors, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff. For more information, please visit: http://www.health.robotics.com

For specific requests, please contact:

Juan Miguel Cana, General Manager
juanmiguel.cana@grifols.com
Phone: +1-323-229-0707

Claudia Flaim, Marketing Coordinator
flaim@health-robotics.com

SOURCE Health Robotics


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES